We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 1 of 1 for:    converce
Previous Study | Return to List | Next Study

Vemurafenib and Cobimetinib Combination in BRAF Mutated Melanoma With Brain Metastasis (CONVERCE)

This study is currently recruiting participants.
Verified September 2016 by Center Eugene Marquis
Sponsor:
ClinicalTrials.gov Identifier:
NCT02537600
First Posted: September 1, 2015
Last Update Posted: December 5, 2016
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
Information provided by (Responsible Party):
Center Eugene Marquis
  Purpose
The purpose of this study is to determine wether cobimetinib + vemurafenib combination treatment is effective in the treatment of BRAFV600-mutated melanoma patients with brain metastasis

Condition Intervention Phase
Malignant Melanoma Drug: Cobimetinib + Vemurafenib combination treatment Phase 2

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Evaluation of Cobimetinib + Vemurafenib Combination Treatment in Patients With Brain Metastasis BRAFV600 Mutated Cutaneous Melanoma

Resource links provided by NLM:


Further study details as provided by Center Eugene Marquis:

Primary Outcome Measures:
  • Complete or partial intracranial response rate in cohort A on the evaluation of each patient's best tumor response by the centralized review committee according to modified Response Evaluation Criteria In Solid Tumors (RECIST) 1.1 criteria. [ Time Frame: From baseline up to 36 months ]

Secondary Outcome Measures:
  • Complete or partial intracranial response rates in cohorts B and C based on the evaluation of each patient's best tumor response by the centralized review committee according to modified RECIST 1.1 criteria. [ Time Frame: Up to 36 months ]
  • Intracranial duration of response (DR) in cohorts A, B and C. [ Time Frame: Up to 36 months ]
  • Overall response rate of cohorts A, B and C [ Time Frame: Up to 36 months ]
  • Overall survival in cohorts A, B and C [ Time Frame: Up to 36 months ]
  • Frequency of Adverse events [ Time Frame: Up to 36 months ]
  • Overall duration of response (DR) in cohorts A, B and C. [ Time Frame: Up to 36 months ]
  • Patient free survival in cohorts A, B and C [ Time Frame: Up to 36 months ]

Other Outcome Measures:
  • Ratio between cerebrospinal fluid concentration and plasmatic exposure of vemurafenib and cobimetinib [ Time Frame: At Day15 Cycle 1 ]
  • BRAF mutation rate in circulating DNA tumor [ Time Frame: From baseline up to treatment stop or progression. An average of 8 cycles of treatment is expected. ]

Estimated Enrollment: 137
Study Start Date: December 2015
Estimated Study Completion Date: June 2018
Estimated Primary Completion Date: February 2018 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Cobimetinib + Vemurafenib combination

Every patients will be treated with :

Vemurafenib 1920 mg / day from day 1 to day 28 continuously Cobimetinib 60 mg / day from day 1 to day 21 One cycle = 28 days Intervention = Cobimetinib + Vemurafenib combination treatment. Only one arm.

Drug: Cobimetinib + Vemurafenib combination treatment
Patients will be treated from day 1 to day 28 with Vemurafenib and from day 1 to day 21 with Cobimetinib. Day 1 to Day 28 corresponds to one cycle of treatment.
Other Names:
  • Vemurafenib = Zelboraf (commercial name)
  • Cobimetinib = code number RO5514041/F04

Detailed Description:

Patients will be enrolled into 3 cohorts:

  • Cohort A : Neurologically asymptomatic patients who have not received prior local treatment ;
  • Cohort B. Neurologically asymptomatic patients who have received prior local treatment;
  • Cohort C. Neurologically symptomatic patients who have or have not received prior local treatment Every patients will be treated with Vemurafenib 960 mg PO, twice daily from D1 to D28, continuously

Cobimetinib 60 mg PO, once daily, from D1 to D21 - 1 cycle = 28 days

Treatment will be administered until progression (intracranial or extracranial), unacceptable toxicity, withdrawal of consent, death or decision of the treating investigator.

Patients who develop intracranial or extracranial progression and who, in the opinion of the treating investigator, could benefit from continuing treatment may continue treatment with vemurafenib and cobimetinib after approval from the principal investigator.

Patients who discontinue the study treatment will undergo an end-of-treatment visit 30 days after the last dose of vemurafenib and/or cobimetinib.

Patients who discontinue the study treatment for any reason other than progression (e.g. toxicity) must be followed up every 8 weeks unless they withdraw their consent.

  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Men and women ≥ 18 years of age.
  2. Histologically confirmed metastatic cutaneous melanoma, mucous melanoma, or melanoma of unknown primary origin (stage IV).
  3. Documented BRAFV600 mutation determined in a hospital center specializing in the molecular genetics of cancer that is certified by the French national cancer institute (INCa).
  4. Presence of Brain Metastases (BM) for which surgical resection is not a reasonable treatment option but that may be amenable to treatment with targeted therapy, to be decided in the onco-dermatology and/or neuro-oncology multidisciplinary team meeting (MDTM).
  5. At least one measurable BM in at least one dimension between 5 and 40 mm on magnetic resonance imaging (MRI) with gadolinium (modified RECIST 1.1).
  6. Patients having previously received a maximum of two systemic therapies during the metastatic phase, except BRAF, Map ERK Kinase (MEK) or Extracellular signal Regulated Kinase (ERK) inhibitors or tyrosine kinase pan-inhibitors (TKIs); prior ipilimumab therapy is allowed if patients have documented cerebral progression 12 weeks after the last injection of treatment and if MRI confirms progression at least 4 weeks later. A period of at least 6 weeks must be observed between the last dose of ipilimumab and the first administration of the study treatments. Prior treatment with anti-programmed cell death (PD)-1 or anti-PD ligand 1 (PD-L1) is allowed.
  7. For patients who have received prior whole brain radiotherapy or radiosurgery and/or surgery for BM (cohorts B and C) demonstration of a significant progression of at least one lesion according to RECIST 1.1 criteria, . after at least 4 weeks have elapsed since this treatment has ended, and MRI at inclusion must demonstrate a significant progression of at least one lesion according to RECIST 1.1 criteria.
  8. Patients with symptomatic or asymptomatic BM.
  9. Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2.
  10. Patients must have recovered from all the side effects (grade ≤ 1 according to the National Cancer Institute Common Terminology Criteria for Adverse Events, NCI-Common Toxicity Criteria for Adverse Event (CTCAE), version 4.03) of their most recent systemic or local treatment (except alopecia).
  11. Signed and dated informed consent before carrying out any procedures that are specific to the trial and are not procedures (examinations) conducted as part of normal patient care.
  12. Patients willing and able to comply with scheduled visits, treatment schedule, laboratory testing and other trial procedures.
  13. Negative serum pregnancy test within 10 days of the first dose of the study treatment for women of childbearing age. Women of non-childbearing potential may be included if they are surgically sterile or postmenopausal for ≥ 1 year.
  14. Fertile men and women must use an effective method of contraception during treatment and for at least 6 months after the last administration of the study treatment. Effective methods of contraception are defined as those that have a low failure rate (i.e. less than 1% per year) when used consistently and correctly, such as injectable implants combined with oral contraception or intra-uterine devices, or as total abstinence in cases where the lifestyle of the patient ensures compliance.
  15. Adequate hematologic, renal and hepatic function within 14 days of the administration of treatment:

Hematologic Leucocytes > 2.0 x 109/L Neutrophils > 1.0 x 109/L Hemoglobin (transfusion allowed) > 9 g/dL Platelets > 100 x 109/L Liver Total bilirubin < 1.5 x upper limit of normal (ULN) (< 3.0 mg/dL for patients with Gilbert syndrome) Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) < 3 x ULN (< 5 x ULN if there is liver metastasis) Alkaline phosphatase (ALP) < 3 x ULN (< 5 x ULN if there is liver or bone metastasis) Kidney Creatinine Or creatinine clearance < 1.5 x ULN ≥ 40 mL/min (Cockcroft-Gault formula)

Exclusion Criteria:

  1. Uveal melanoma. Patients with mucous melanoma or melanoma of unknown primary origin are eligible if BRAFV600 mutation is confirmed.
  2. Symptomatic or diffuse leptomeningeal involvement.
  3. Symptoms of uncontrolled intracranial pressure. Increasing corticosteroid dose during the 7 days prior to the first dose of the study treatment is an exclusion criterion. Patients receiving corticosteroids and patients presenting intermittent seizures may be enrolled if the dose of corticosteroids and anti-epileptic treatments has been stable for at least 2 weeks before inclusion.
  4. Indication for urgent neurosurgery or radiotherapy.
  5. Prior malignancy active within the previous 3 years except for locally curable cancers that have been treated to complete remission or untreated stage I chronic lymphoid leukemia.
  6. Known human immunodeficiency virus (HIV) infection.
  7. Prior treatment with BRAF, MEK, or ERK inhibitors or pan-TKIs.
  8. Concurrent administration of any anticancer therapies other than those administered in this study.
  9. Treatment with any cytotoxic and/or investigational drug or targeted therapy within 4 weeks of the first dose of the study treatment, or ipilimumab, anti-PD-1 or anti-PD-L1 immunotherapy within 8 weeks of the study treatment and/or radiation therapy within 2 weeks of the study treatment.
  10. Pregnant or breastfeeding women.
  11. Refractory nausea and vomiting, intestinal malabsorption, or significant bowel resection that would preclude adequate absorption or cause an inability to swallow tablets.
  12. Ulcerative colitis, erosive esophagitis or gastritis, infectious or inflammatory bowel disease, diverticula or other gastrointestinal condition increasing the risk of perforation.
  13. Any of the following within the 6 months prior to the first dose of study treatment:

    • myocardial infarction,
    • severe/unstable angina,
    • symptomatic congestive heart failure (New York Heart Association grade ≥2),
    • cerebrovascular accident or transient ischemic attack,
    • pulmonary embolism,
    • grade > 2 hypertension not controlled by medications.
  14. History or presence of clinically significant ventricular or atrial arrhythmia ≥ grade 2 (NCI-CTCAE Version 4.03).
  15. Corrected QT (cQT) interval ≥ 450 ms and left ventricular ejection fraction (LVEF) below the lower limit of normal (LLN) or < 50% (scintigraphy or ultrasound).
  16. History, risk factor or retinal pathology that increases the risk of retinal vein occlusion (RVO) or central serous retinopathy (CSR): evidence of retinal pathology that is considered a risk factor for RVO or CSR, or a history of retinal detachment, central serous chorioretinopathy or retinal vein thrombosis. The risk factors for RVO are listed below:

    • Uncontrolled glaucoma with intraocular pressures > 21 mm Hg,
    • Serum cholesterol ≥ Grade 2 (≥ 7.75 mmol/L),
    • Hypertriglyceridemia ≥ Grade 2 (≥ 3.42 mmol/L),
    • Hyperglycemia (fasting) ≥ Grade 2 (≥ 8.9 mmol/L).
  17. Serious or uncontrolled medical disorders that, in the opinion of the investigator, may increase the risk associated with study participation or study drug administration, impair the ability of the patient to follow the protocol, or interfere with the interpretation of study results.
  18. Patients Under guardianship or curators, maintenance of justice, non-informed about diagnosis, unable to follow study medical requirement for geographical, social or psychic reasons.
  19. Patients with abnormal blood electrolyte test (Ca, Mg, K and Na) that could not be corrected.
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02537600


Contacts
Contact: Martine Gestin +33 2 99 25 30 36 m.gestin@rennes.unicancer.fr

Locations
France
CHU de Bordeaux Not yet recruiting
Bordeaux, France, 33000
Principal Investigator: Caroline DUTRIAUX         
CHU Ambroise Paré Recruiting
Boulogne, France, 92104
Principal Investigator: Philippe SAIAG, Professor         
CHU Brest - Hôpital Morvan Recruiting
Brest, France
Principal Investigator: Delphine LEGOUPIL         
CHU Caen - Hôpital Clémenceau Recruiting
Caen, France, 14033
Principal Investigator: Michel DE PONTVILLE, MD         
Hôpital Henri Mondor Recruiting
Creteil, France, 94010
Principal Investigator: Ouidad ZEHOU         
CHU de Dijon Not yet recruiting
Dijon, France
Principal Investigator: Sophie DALAC-RAT         
CHU Albert Michallon Recruiting
Grenoble, France, 38014
Principal Investigator: Marie-Thérèse LECCIA         
Centre Hospitalier du Mans Recruiting
Le Mans, France, 72037
Principal Investigator: Nathalie BENETON         
CHRU Lille Recruiting
Lille, France, 59037
Principal Investigator: Laurent MORTIER, Professor         
Centre Hospitalier Lyon Sud Not yet recruiting
Lyon, France, 69495
Principal Investigator: Stéphane DALLE         
Centre Hospitalier Annecy Genevois Not yet recruiting
Metz-Tessy, France, 74370
Principal Investigator: Julie DE QUATREBARBES         
CHU de Nantes Not yet recruiting
Nantes, France, 44093
Principal Investigator: Brigitte DRENO         
Groupe Hospitalier l'Archet Recruiting
Nice, France, 06202
Principal Investigator: Jean-Philippe LACOUR, Professor         
CHR Orléans Not yet recruiting
Orléans, France, 45032
Principal Investigator: Guido BENS, MD         
Hôîtal St louis Recruiting
Paris, France, 75010
Principal Investigator: Céleste LEBBE, Professor         
Hôpital Cochin Recruiting
Paris, France, 75014
Principal Investigator: Nora KRAMKIMEL         
Hôpital Bichat Not yet recruiting
Paris, France, 75018
Principal Investigator: Eve MAUBEC, MD         
Centre Eugène Marquis Recruiting
Rennes, France, 35042
Principal Investigator: Thierry Lesimple, MD         
Hôpital Charles Nicolle - CHU Rouen Not yet recruiting
Rouen, France, 76031
Principal Investigator: Anne-Bénédicte DUVAL-MODESTE         
Institut Claude Regaud Not yet recruiting
Toulouse, France
Principal Investigator: Nicolas MEYER         
CHU Tours Recruiting
Tours, France, 37044
Principal Investigator: Laurent MACHET, Professor         
Institut Gustave Roussy Not yet recruiting
Villejuif, France, 94805
Principal Investigator: Caroline ROBERT         
Sponsors and Collaborators
Center Eugene Marquis
Investigators
Principal Investigator: Thierry Lesimple, MD Centre Eugène Marquis
  More Information

Responsible Party: Center Eugene Marquis
ClinicalTrials.gov Identifier: NCT02537600     History of Changes
Other Study ID Numbers: 2013-TL-MEL-Th
2014-001671-30 ( EudraCT Number )
First Submitted: August 18, 2015
First Posted: September 1, 2015
Last Update Posted: December 5, 2016
Last Verified: September 2016

Keywords provided by Center Eugene Marquis:
BRAF mutation
Brain metastasis
Cobimetinib + Vemurafenib combination treatment

Additional relevant MeSH terms:
Melanoma
Neoplasm Metastasis
Neuroendocrine Tumors
Neuroectodermal Tumors
Neoplasms, Germ Cell and Embryonal
Neoplasms by Histologic Type
Neoplasms
Neoplasms, Nerve Tissue
Nevi and Melanomas
Neoplastic Processes
Pathologic Processes
Vemurafenib
Antineoplastic Agents
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action